Medivir
  • About us
  • Our projects
  • About cancer
  • Investors
  • News and media
  • Connect
  • Svenska
About us
  • Medivir in brief
    • Business concept & Strategy
      • Leadership
        • Management team
        • Board of Directors
      • History
        • EFPIA Disclosure
          Our projects
          • Proprietary
            • Fostroxacitabine bralpamide (fostrox)
          • Projects for licensing
            • Remetinostat
            • MIV-711
          • Partnerships
            • Birinapant/IGM-9427
            • Xerclear®
            • USP-7
            • MBLI/MET-X
          • Publications
            About cancer
            • About cancer
              Investors
              • Stock information
                • Reports
                  • Financial Reports 2024
                  • Financial Reports 2023
                  • Financial Reports 2022
                  • Financial reports 2021
                  • Financial reports 2020
                  • Financial reports 2019
                  • Financial reports 2018
                  • Financial reports 2017
                  • Financial reports 2016
                  • Financial reports 2015
                • Presentations
                  • Presentations 2024
                  • Presentations 2023
                  • Presentations 2022
                  • Presentations 2021
                  • Presentations 2020
                  • Presentations 2019
                • Press releases
                  • Calendar
                    • Redeye Technology & Life Science Day
                    • Redeye Fight Cancer event 2025
                    • Year-End Report, January - December 2024 (webcast)
                    • Interim Report, January - March 2025 (webcast)
                    • Annual General Meeting 2025
                  • Corporate Governance
                    • General Meetings
                      • 2024
                      • 2023
                      • 2022
                      • 2021
                      • 2020
                      • 2019
                      • 2018
                      • 2017
                      • 2016
                    • Rights issue 2023
                      News and media
                        Connect
                        • Connect with Medivir
                          • Partner with Medivir
                            Search
                            Subscribe to press releases
                            Address

                            Medivir AB
                            Box 1086
                            SE-141 22 Huddinge
                            Visit: Lunastigen 5, 2nd floor

                            Phone +46 (0)8 5468 31 00 Email info@medivir.com
                            Our privacy policy

                            Read more

                             

                            Jens Lindberg

                            Chief Executive Officer

                            jens.lindberg@medivir.com
                             

                            Magnus Christensen

                            Chief Financial Officer

                            magnus.christensen@medivir.com